<?xml version='1.0' encoding='UTF-8'?>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">3010204</PMID>
<DateCreated>
<Year>1986</Year>
<Month>06</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>1986</Year>
<Month>06</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>10</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0029-7844</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>67</Volume>
<Issue>6</Issue>
<PubDate>
<Year>1986</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Obstetrics and gynecology</Title>
<ISOAbbreviation>Obstet Gynecol</ISOAbbreviation>
</Journal>
<ArticleTitle>Second-look laparotomy in the management of malignant germ cell tumors of the ovary.</ArticleTitle>
<Pagination>
<MedlinePgn>789-93</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>From 1970 to 1985, 53 patients with malignant nondysgerminomatous germ cell tumors of the ovary underwent second-look laparotomy after initial surgery and combination chemotherapy. Twenty-two patients had immature teratoma, 15 had endodermal sinus tumor, 15 had mixed germ cell tumor, and one patient had embryonal carcinoma. Thirty-one of the neoplasms were stage I, four were stage II, 17 were stage III, and one was stage IV. Two patients received a combination of actinomycin-D, 5-fluorouracil, and cyclophosphamide; four patients received vinblastine, bleomycin, and cisplatin; 44 patients received vincristine, actinomycin-D, and cyclophosphamide; and three patients received a combination of the last two regimens. Second-look findings were negative in 52 patients and positive in one patient who was subsequently salvaged with further chemotherapy. One patient with stage I endodermal sinus tumor relapsed nine months after a negative second-look laparotomy and died. Two patients with negative findings subsequently died of leukemia. Of 53 patients undergoing second-look laparotomy, three are dead (one of cancer and two of leukemia), and 50 patients are surviving without disease. Although the precise role of second-look laparotomy in patients with malignant germ cell tumors is yet to be established, possible indications are discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gershenson</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Copeland</LastName>
<ForeName>L J</ForeName>
<Initials>LJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>del Junco</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Edwards</LastName>
<ForeName>C L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wharton</LastName>
<ForeName>J T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rutledge</LastName>
<ForeName>F N</ForeName>
<Initials>FN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Obstet Gynecol</MedlineTA>
<NlmUniqueID>0401101</NlmUniqueID>
<ISSNLinking>0029-7844</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D007813">Laparotomy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009373">Neoplasms, Germ Cell and Embryonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012086">Reoperation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
